your market intelligence analyst
Search Results
Edit Save
1,059 results
SynBioBeta 06/02/2020 06:34
SILICON VALLEY, Calif., June 2, 2020 /PRNewswire/ — Modular Bioscience, an early stage biotechnology company based in Silicon Valley, today announced that it has executed a definitive agreement with the University of Illinois at Urbana-Champaign for an exclusive global patent license to a novel artificial restriction enzyme (ARE) platform.
SynBioBeta 06/02/2020 06:31
First enzymes will target NGS-based diagnostics, RNA-directed viral diagnostics and RNA manufacturing REDWOOD CITY, Calif. and JUPITER, Fla., June 01, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes, announce [...]. .
SynBioBeta 06/01/2020 07:39
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ — Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities Regeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product development Intellia receives $100 million through upfront cash and equity investment Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. [...]. .
SynBioBeta 06/01/2020 06:31
– SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma – CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ — Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical [...]. .
SynBioBeta 05/30/2020 06:34
LexaGene Places a Pre-Commercial Instrument for COVID-19 Testing in a Major Hospital Laboratory BEVERLY, Mass. – May 28, 2020 – LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the "Company") a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, is pleased to announce the placing of a pre-commercial instrument that tests for COVID-19 [...]. .
SynBioBeta 05/30/2020 06:30
With extended applications, Tapestri Designer, the only AI-powered cloud-based tool for single-cell panel designs, will improve drug development and CRISPR quality control studies South San Francisco, CALIF. – WEBWIRE – Thursday, May 28, 2020 Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced extended capabilities for Tapestri Designer, the first-ever automated, cloud-based tool […]. .
SynBioBeta 05/27/2020 06:36
Vancouver, Canada — May 26, 2020 — Renaissance BioScience Corp. (RBSC), a leading global bioengineering company, is pleased to announce that it will receive advisory services and a multi-year, non-repayable contribution of up to $493,625 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
SynBioBeta 05/23/2020 07:31
AbCellera will use its world-leading antibody drug discovery platform in a multi-year collaboration to identify antibodies against up to nine targets May 22, 2020 05:28 PM Eastern Daylight Time VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the [...]. .
SynBioBeta 05/22/2020 07:04
Sales Significantly Exceeding Expectations EMERYVILLE, Calif., May 21, 2020 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the launch of "Baby Cream to Powder" under its Pipette™ baby brand giving caring parents more choice [...]. .
SynBioBeta 05/22/2020 06:59
Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future. May 21, 2020 06:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it […]. .
SynBioBeta 05/22/2020 06:54
SHANGHAI and WORCESTER, Mass., May 18, 2020 /PRNewswire/ — WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business Development Corporation (WBDC) announced today the successful signing of a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus.
SynBioBeta 05/21/2020 08:58
Sherlock Innovation Lab to Stimulate New England Economy by Creating New Jobs for Industry and Academic Experts Impacted by COVID-19 Pandemic Funding to Accelerate Development of INSPECTR™ Rapid Diagnostic Platform to Improve Testing in At-home and Low-resource Settings May 21, 2020 08:30 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sherlock Biosciences, an Engineering Biology company dedicated to [...]. .
SynBioBeta 05/21/2020 07:57
CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ — Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical company, for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease (IBD).
SynBioBeta 05/20/2020 09:12
Acquisition enables full integration of R&D and production for ongoing and future xenotransplant programs Contract production partner will become a wholly-owned subsidiary of eGenesis CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) — eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address [...]. .
SynBioBeta 05/20/2020 09:02
Company also Applying its High-throughput RNA-amplicon Sequencing Platform to Accelerate COVID-19 Testing Efforts May 20, 2020 08:30 AM Eastern Daylight Time EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised $30 million in a Series A financing led by venture [...]. .

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications